Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15198045 | 0.98 | CYP1A2 (0.68) | HRH3CYP1A2CYP2D6HRH1EPHX2 | |
| SCHEMBL15198042 | 0.97 | HRH3 (0.62) | HRH3CYP1A2CYP2D6HRH1EPHX2 | |
| SCHEMBL15198044 | 0.93 | HRH3 (0.57) | HRH3CYP1A2CYP2D6 | |
| SCHEMBL25782607 | 0.90 | HRH3 (0.55) | HRH3CYP1A2CYP2D6HRH1L3MBTL1 | |
| SCHEMBL15759178 | 0.89 | CYP1A2 (0.56) | HRH3CYP1A2CYP2D6HRH1L3MBTL1 | |
| SCHEMBL13257862 | 0.85 | HRH3 (0.50) | HRH3CYP1A2CYP2D6CYP3A4SMN1; SMN2 | |
| SCHEMBL18595229 | 0.85 | HRH3 (0.50) | HRH3CYP1A2CYP2D6HRH1TDP1 | |
| SCHEMBL12894384 | 0.82 | HRH3 (0.53) | HRH3CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL12064 | 0.81 | HRH3 (0.55) | HRH3CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL13990825 | 0.80 | HRH3 (1.00) | HRH3CYP1A2CYP2D6EPHX2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| EP-2493889-B1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9511060-B2 | Non-flushing niacin analogues, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160151343-A1 | NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE | 2016-06-02 | — | — | US | disclosed |
| US-7598392-B2 | 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-10-06 | — | — | US | disclosed |
| US-7598392-B2 | 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-10-06 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH3 3986/4885CYP1A2 95/4885CYP2D6 79/4885 |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | PKD2, TPMT, PKD1 | HRH3 724/4885CYP1A2 277/4885CYP2D6 21/4885 |
| US-20160151343-A1 | NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF | SLC33A1, CHLSN, APOB | HRH3 358/4885CYP1A2 2659/4885CYP2D6 3339/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 1893/4885CYP1A2 754/4885CYP2D6 1257/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885CYP1A2 530/4885CYP2D6 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.